• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常染色体显性遗传和晚发性阿尔茨海默病认知衰退的不同速率。

Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.

机构信息

Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.

Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.

出版信息

Alzheimers Dement. 2022 Oct;18(10):1754-1764. doi: 10.1002/alz.12505. Epub 2021 Dec 2.

DOI:10.1002/alz.12505
PMID:34854530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9160203/
Abstract

As prevention trials advance with autosomal dominant Alzheimer disease (ADAD) participants, understanding the similarities and differences between ADAD and "sporadic" late-onset AD (LOAD) is critical to determine generalizability of findings between these cohorts. Cognitive trajectories of ADAD mutation carriers (MCs) and autopsy-confirmed LOAD individuals were compared to address this question. Longitudinal rates of change on cognitive measures were compared in ADAD MCs (n = 310) and autopsy-confirmed LOAD participants (n = 163) before and after symptom onset (estimated/observed). LOAD participants declined more rapidly in the presymptomatic (preclinical) period and performed more poorly at symptom onset than ADAD participants on a cognitive composite. After symptom onset, however, the younger ADAD MCs declined more rapidly. The similar but not identical cognitive trajectories (declining but at different rates) for ADAD and LOAD suggest common AD pathologies but with some differences.

摘要

随着常染色体显性阿尔茨海默病 (ADAD) 预防试验的推进,了解 ADAD 与“散发性”晚发性 AD (LOAD) 之间的异同对于确定这些队列之间的研究结果的可推广性至关重要。为了解决这个问题,比较了 ADAD 突变携带者 (MCs) 和尸检确诊的 LOAD 个体的认知轨迹。比较了 ADAD MCs (n=310) 和尸检确诊的 LOAD 参与者 (n=163) 在症状出现前后 (估计/观察到) 的认知测量的纵向变化率。LOAD 参与者在无症状前 (临床前) 期下降更快,在症状出现时的认知综合表现比 ADAD 参与者差。然而,在症状出现后,较年轻的 ADAD MCs 下降更快。ADAD 和 LOAD 的认知轨迹相似但不相同(下降但速度不同)表明存在共同的 AD 病理,但存在一些差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/977e/9160203/454328a8ab84/nihms-1762709-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/977e/9160203/ea932ad0edf0/nihms-1762709-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/977e/9160203/454328a8ab84/nihms-1762709-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/977e/9160203/ea932ad0edf0/nihms-1762709-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/977e/9160203/454328a8ab84/nihms-1762709-f0002.jpg

相似文献

1
Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.常染色体显性遗传和晚发性阿尔茨海默病认知衰退的不同速率。
Alzheimers Dement. 2022 Oct;18(10):1754-1764. doi: 10.1002/alz.12505. Epub 2021 Dec 2.
2
Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.迟发性常染色体显性遗传和散发性阿尔茨海默病之间的表型相似性:一项单家族病例对照研究。
JAMA Neurol. 2016 Sep 1;73(9):1125-32. doi: 10.1001/jamaneurol.2016.1236.
3
Functional connectivity in autosomal dominant and late-onset Alzheimer disease.常染色体显性和晚发性阿尔茨海默病中的功能连接性
JAMA Neurol. 2014 Sep;71(9):1111-22. doi: 10.1001/jamaneurol.2014.1654.
4
Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease.比较晚发性和常染色体显性阿尔茨海默病的皮质萎缩特征。
Neuroimage Clin. 2020;28:102491. doi: 10.1016/j.nicl.2020.102491. Epub 2020 Nov 5.
5
APOE ε4 influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal-dominant Alzheimer's disease.载脂蛋白 E ε4 对常染色体显性阿尔茨海默病的 APP 和 PSEN1 突变携带者的认知衰退有积极影响,对其有负面影响。
Eur J Neurol. 2022 Dec;29(12):3580-3589. doi: 10.1111/ene.15536. Epub 2022 Sep 11.
6
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.测试淀粉样蛋白级联假说:常染色体显性阿尔茨海默病的预防试验。
Alzheimers Dement. 2022 Dec;18(12):2687-2698. doi: 10.1002/alz.12624. Epub 2022 Feb 24.
7
H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease.临床前常染色体显性阿尔茨海默病的 H MRS 光谱学。
Brain Imaging Behav. 2019 Aug;13(4):925-932. doi: 10.1007/s11682-018-9913-1.
8
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).常染色体显性遗传性家族性阿尔茨海默病的神经学表现:已发表文献与显性遗传阿尔茨海默病网络观察性研究(DIAN-OBS)的比较
Lancet Neurol. 2016 Dec;15(13):1317-1325. doi: 10.1016/S1474-4422(16)30229-0. Epub 2016 Oct 21.
9
Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study.哥伦比亚常染色体显性阿尔茨海默病家族中的认知衰退:一项回顾性队列研究。
JAMA Neurol. 2016 Apr;73(4):431-8. doi: 10.1001/jamaneurol.2015.4851.
10
Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN).两项多中心纵向观察性研究参与者的神经病理学评估:阿尔茨海默病神经影像学倡议(ADNI)和显性遗传性阿尔茨海默病网络(DIAN)。
Neuropathology. 2015 Aug;35(4):390-400. doi: 10.1111/neup.12205. Epub 2015 May 12.

引用本文的文献

1
The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation.CentiMarker项目:使阿尔茨海默病生物标志物定量标准化以用于生物学解释。
Alzheimers Dement. 2025 Apr;21(4):e14587. doi: 10.1002/alz.14587.
2
Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome.常染色体显性阿尔茨海默病和唐氏综合征中体液生物标志物的临床和研究应用。
EBioMedicine. 2024 Oct;108:105327. doi: 10.1016/j.ebiom.2024.105327. Epub 2024 Oct 3.
3
15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN.
糖尿病预防试验(DIAN)中15年的纵向基因、临床、认知、影像学和生化测量
medRxiv. 2024 Aug 9:2024.08.08.24311689. doi: 10.1101/2024.08.08.24311689.
4
The CentiMarker Project: Standardizing Quantitative Alzheimer's disease Fluid Biomarkers for Biologic Interpretation.CentiMarker项目:标准化用于生物学解释的阿尔茨海默病定量生物标志物
medRxiv. 2024 Jul 27:2024.07.25.24311002. doi: 10.1101/2024.07.25.24311002.
5
CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.常染色体显性阿尔茨海默病的 CSF 蛋白质组学研究突出了与散发性疾病的相似之处。
Brain. 2023 Nov 2;146(11):4495-4507. doi: 10.1093/brain/awad213.
6
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer's disease.一种经过生物标志物验证的疾病进展时间尺度,已经确定了散发性阿尔茨海默病的早发和晚发亚组。
Alzheimers Res Ther. 2023 May 2;15(1):89. doi: 10.1186/s13195-023-01231-8.
7
Sex difference in evolution of cognitive decline: studies on mouse model and the Dominantly Inherited Alzheimer Network cohort.认知衰退演变中的性别差异:基于小鼠模型和显性遗传性阿尔茨海默病网络队列的研究。
Transl Psychiatry. 2023 Apr 12;13(1):123. doi: 10.1038/s41398-023-02411-8.
8
Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology.常染色体显性遗传和散发性晚发性阿尔茨海默病具有共同的体内病理生理学。
Brain. 2022 Oct 21;145(10):3594-3607. doi: 10.1093/brain/awac181.